Editorial: CML HSCs: Are the True Enemies for the Patient?

Curr Drug Targets. 2017;18(4):376. doi: 10.2174/138945011804170206191356.

Author

Manuela Mancini¹

Affiliation

¹ PhD-DIMES-Institute of Hematology "L. e A. Seragnoli" University of Bologna via Massarenti, 9-40138 Bologna, Italy.

PMID: 28264644
DOI: 10.2174/138945011804170206191356

No abstract available

Publication types

Editorial
Introductory Journal Article

MeSH terms

Antineoplastic Agents / pharmacology*
Antineoplastic Agents / therapeutic use
Drug Resistance, Neoplasm / genetics
Fusion Proteins, bcr-abl / genetics
Fusion Proteins, bcr-abl / metabolism*
Hematopoietic Stem Cells / drug effects
Hematopoietic Stem Cells / metabolism*
Hematopoietic Stem Cells / pathology
Humans
Imatinib Mesylate / pharmacology
Imatinib Mesylate / therapeutic use
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology*
Neoplastic Stem Cells / drug effects
Neoplastic Stem Cells / metabolism*
Neoplastic Stem Cells / pathology
Treatment Outcome

Substances

Antineoplastic Agents
Imatinib Mesylate
Fusion Proteins, bcr-abl